PARP1 Cancer Research Results

PARP1, Poly [ADP-ribose] polymerase 1: Click to Expand ⟱
Source:
Type:
PARP1 accounts for 90% of the PARP family of enzymes. PARP-1 (poly(ADP-ribose)-polymerase 1), mainly known for its protective role in DNA repair, also regulates inflammatory processes.
The close connection between PARP1 and the tumor suppressor protein p53 is also of great interest to those who study the complex role of PARP1 in cancer promotion or suppression.
PARP1 inhibition, which blocks the JNK-PARP1-JNK loop and ERK-mediated anti-apoptotic protein expression, will result in cancer apoptosis.

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Mye, Myeloma: Click to Expand ⟱

Myeloma - Plasma Cell Malignancy

Alternative Names: Multiple myeloma, plasma cell myeloma

Type: Hematologic malignancy / plasma cell cancer

Origin: Malignant transformation and clonal expansion of antibody-producing plasma cells, usually within the bone marrow.

Function/Characteristics: Myeloma cells produce monoclonal immunoglobulins or light chains and can disrupt normal bone marrow function, bone remodeling, renal function, and immune regulation.

Common Features: Bone marrow infiltration, osteolytic bone lesions, anemia, elevated monoclonal protein, renal dysfunction, hypercalcemia, and impaired normal antibody production.

Common Markers: CD38, CD138, BCMA (TNFRSF17), SLAMF7, and monoclonal immunoglobulin/light-chain expression.
Scientific Papers found: Click to Expand⟱
7437- CYN,    Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma
- in-vitro, Mye, AMO1 - in-vivo, Mye, NA - in-vitro, Mye, KMS11 - in-vitro, Mye, JJN3 - in-vitro, Mye, MolP8 - in-vitro, Mye, L363 - in-vitro, Mye, H929
tumCV↓, cMyc↓, STAT3↓, Akt↓, ERK↓, TumCCA↑, DNAdam↑, PARP1↑, AIF↑, TumCG↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   PARP1↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   STAT3↓, 1,   TumCG↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PARP1, Poly [ADP-ribose] polymerase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:92  Cells:%  prod#:%  Target#:400  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page